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Abstract 
Purpose: To present an alternative method for summing biologically effective doses of intensity-modulated arc 
therapy (IMAT) as teletherapy (TT), with interstitial high-dose-rate (HDR) brachytherapy (BT) boost in prostate cancer. 
Total doses using IMAT boost was compared with BT boost using our method.
Material and methods: Initially, 25 IMAT TT plus interstitial HDR-BT plans were included, and additional plans 
using IMAT TT boost were created. The prescribed dose was 2/44 Gy to the whole pelvis, 2/60 Gy to the prostate and 
seminal vesicles, and 1 × 10 Gy BT or 2/18 Gy IMAT TT to the prostate. Teletherapy computed tomography (CT) was 
registered with ultrasound (US) of BT, and the most exposed volume of critical organs in BT were identified on these 
CT images. The minimal dose of these from IMAT TT was summed with their BT dose, and these EQD2 doses were 
compared using BT vs. IMAT TT boost. This method was compared with uniform dose conception (UDC).
Results: D90 of the prostate was significantly higher with BT than with IMAT TT boost: 99.3 Gy vs. 77.9 Gy, 
p = 0.0034. The D2 to rectum, bladder, and hips were 50.3 Gy vs. 76.8 Gy (p = 0.0117), 64.7 Gy vs. 78.3 Gy (p = 0.0117), 
and 41.9 Gy vs. 50.6 Gy (p = 0.0044), while D0.1 to urethra was 96.1 Gy vs. 79.3 Gy (p = 0.0180), respectively. UDC over-
estimated D2 (rectum) by 37% (p = 0.0117), D2 (bladder) by 5% (p = 0.0214), and underestimated D0.1 (urethra) by 1% 
(p = 0.0277).
Conclusions: Based on our biological dose summation method, the total dose of prostate is higher using BT boost 
than the IMAT. BT boost yields lower rectum, bladder, and hips doses, but higher dose to urethra. UDC overestimates 
rectum and bladder dose and underestimates the dose to urethra. 
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Purpose
The standard of care in curative treatment of inter-
mediate- and high-risk prostate cancer is external beam 
radiotherapy (teletherapy – TT) and high-dose-rate 
(HDR) interstitial brachytherapy (BT) boost with andro-
gen deprivation therapy. Since the α/β value of prostate 
tumor is low, dose escalation has an essential role in the 
development of both radiotherapy modalities [1,2]. The 
more complex the techniques, the more they can esca-
late the dose to the tumor while sparing organs at risk 
(OARs). The state-of-the-art radiotherapy combination is 
intensity-modulated arc therapy (IMAT) as TT and im-
age-guided interstitial BT [3,4]. These complex treatments 
require reliable reporting of the dose received by tumor 
and critical structures. 
The use of BT boost has been linked with improved 
biochemical progression-free and overall survival [5,6]. 
What is more, modern HDR-BT approach results in im-
proved quality of life with lower acute urinary and rectal 
toxicity [7], and with the dose coverage of target volume 
(D90, the minimum dose delivered to 90% of prostate) cor-
relating with local tumor control [8] and the dose of the 
most exposed part of OARs with normal tissue toxicity [9]. 
To achieve reporting these dose-volume parameters 
properly, overall volumetric doses must be properly in-
tegrated with tele- and brachytherapy. As simple physical 
dose summation does not take into consideration different 
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biological effects, the equivalent dose given in 2 Gy frac-
tions (EQD2) must be calculated [10,11]. The dose distri-
bution of TT is assumed to be completely uniform, so the 
dose from TT is considered as the target volume, and the 
nearest OARs receive the entire prescribe dose. Then, this 
equivalent uniform dose is calculated for dose summation 
with BT doses (uniform dose conception – UDC) [12]. On 
the other hand, this assumption can be suitable for conven-
tional four-field box TT plans but an improper approach 
for IMAT plans, where the dose intensity is modulated. 
In addition, in the IMAT TT technique, the most exposed 
2 cm3 of OARs is not a compact volume, since its voxels 
are dispersed in organ, as we have reported earlier [13]. 
It was also shown that the most exposed part of OARs in 
the summed plans is in the same region that receives the 
largest dose in BT. Nevertheless, this 2 cm3 volume is not 
in the same location as the most exposed part in TT [14]. 
Therefore, simple dose-volume histogram (DVH) addi-
tion sums the dose of two different 2 cm3 volumes. 
In many previous investigations, authors did not con-
sider the real biological dose of prostate and OARs in TT 
in combined TT and BT treatment. Pinkawa et al. [15] used 
the above mentioned UDC method to estimate doses from 
TT and engaged physical BT doses only. Andrzejewski 
et al. [16] compared different advanced radiotherapy 
methods for boosting dominant intraprostatic lesion. They 
calculated biological equivalent doses for comparison but 
did not examine combined therapies. Pieters et al. [17] 
calculated and compared the total doses of 70 Gy, with 
five-beam intensity-modulated TT combined with 6 Gy 
TT boost versus 46 Gy TT with HDR or pulsed-dose-rate 
BT boost complemented to overall 70 Gy EQD2, but for 
low-risk patients where the target volume was only the 
prostate. They redefined the prescribed dose of BT to sum 
the TT and BT plans in dosimetrically equivalent way. Ki-
kuchi et al. [18] made a computed tomography (CT) series 
after BT and calculated the biological effective dose of rec-
tum in TT and BT. They associated this dose to the pixels 
of rectum volume and computed a summarized DVH of 
TT and BT. This was a better estimation of the rectal dose 
than the UDC method, but the quadratic behavior of bio-
logical dose was not considered. Applying the linear-qua-
dratic formula for a dose-volume parameter is not appro-
priate, because the EQD2 dose of a voxel is based on the 
α/β value in the given voxel, which is not homogeneous 
in the body. Therefore, the biological dose must be cal-
culated voxel-by-voxel in the same organ, but currently, 
none of the treatment planning systems apply this feature. 
In the future, the deformable image registration (DIR) 
could be an appropriate method to integrate BT and TT 
doses both for prostate and OARs, but at the moment, it 
results in significant errors at the border of prostate and 
OARs, i.e. the prostate and the rectal wall overlap each oth-
er in registered image. The main problem are foreign bod-
ies (metal or plastic needles and ultrasound [US] probe) 
in situ, which are not present on TT image data sets. In ad-
dition, DIR algorithms cannot handle US data, so CT-CT 
fusion is needed. The image registration of TT CT and CT 
after BT treatment does not use the dose values from the 
real BT plan. The dose gradient is high in BT, so the dose 
distribution can be significantly different in a post-BT plan 
without the needles and US probe than in the actual plan. 
Using doses of the actual plan, where the needles are in 
their real place, is the most adequate method. 
We have developed an alternative dose summation 
method in combined radiotherapy of cervical cancer [14]. 
The aim of the present study was to elaborate on alterna-
tive method for summing the biologically effective doses 
of IMAT TT with interstitial HDR-BT boost in prostate 
cancer and compare it to the recent UDC method. Ad-
ditionally, the total doses of IMAT TT plus HDR-BT vs. 
IMAT TT boost will also be compared using our dose 
summation method. 
Material and methods 
At our institute, twenty-five IMAT TT plus interstitial 
HDR-BT plans of patients with intermediate- and high-risk 
prostate cancer were included for this study. Selection cri-
teria included prostate-specific antigen (PSA) > 10 ng/ml, 
and/or Gleason score (GS) 7-10 and/or stage T2b-T3b. The 
TT was performed in supine position, the patients were 
immobilized with knee and ankle support system. The 
prescribed dose was 2/44 Gy for the whole pelvis, 2/60 Gy 
for the prostate and the seminal vesicles, and was deliv-
ered with an energy of 10 MV, using 2 full arcs. Based on 
our local IGRT protocol, CBCT verification was made from 
1st to 3rd fractions, the systematic error was calculated and 
corrected before the 4th fraction, then weekly verification 
was done for patients’ positioning. TT was complement-
ed with transrectal US-guided interstitial HDR-BT boost, 
performed after 4 weeks of TT course, given 1 fraction of 
10 Gy [19]. After scanning the prostate with US, a virtual 
preimplant plan was generated (Oncentra Prostate v3.1, 
Elekta Brachytherapy, Veendendaal, The Netherlands). 
The whole prostate gland was contoured as the target vol-
ume, and OARs included the rectum (rectal wall), the pros-
tatic-urethra, and the bladder. HIPO optimization method 
was used, and the prescribed dose was 10 Gy to the whole 
prostate gland (V100 ≥ 95%). Based on this plan, metal nee-
dles were inserted into the prostate through a template 
under US guidance. The optimization procedure was used 
again for calculating dwell times in the inserted needles to 
achieve final dose distribution. The detailed description of 
our treatment method can be found in our previous publi-
cations [20,21]. The total treatment time of TT and BT was 
7 weeks (range, 44-54 days). In clinical routine, the UDC 
method was used to determine the dose constraints for 
prostate and OARs in BT implant and their total doses. 
First, the treatment planning CT for TT was registered 
with the US BT set in BT treatment planning system in 
every case (Figure 1). During the manual registration, the 
TT CT set was shifted and rotated to place together the 
prostate gland of BT and TT plans, and rectal walls of the 
two plans. Then, the TT CT with BT plan was imported 
to the TT planning system (Eclipse v13.7, Varian Medical 
Systems, Palo Alto, USA). 
Then, the localization of the most exposed part of 
OARs from the sum of TT and BT plans was investigated. 
The most exposed part of hips (femoral heads) is always 
the nearest volume to the prostate and the dose contri-
bution from BT is practically zero. Therefore, the most 
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exposed 0.1 and 2 cm3 of hips were calculated only from 
the TT plan. The most exposed part of the rectum, ure-
thra, and bladder is in the region where the dose maxi-
mum is in BT. So, the most exposed 0.1 and 2 cm3 from 
BT were determined in the TT CTs, and the intersection 
of this volumes and given organ was created (Figure 2). 
The minimal dose of this intersection was calculated in 
TT plans and summed with the dose of this volumes from 
BT using the linear-quadratic radiobiological model. The 
α/β of prostate tumor was assumed as 1.5 Gy [22,23,24], 
while for OARs, 3 Gy was used. The minimum dose de-
livered to 90% of the prostate (D90) was calculated in the 
TT and BT plans, and these doses were summed using 
also the linear-quadratic model. 
The following dose-volume parameters were used for 
quantitative evaluation of the plans: D90 – the minimum 
dose delivered to 90% of prostate (Gy), D0.1 (x) – the mini-
mal dose of the most exposed 0.1 cm3 of the critical organ 
x (Gy), where x were the rectum, urethra, bladder, or hips. 
D2 (x) – the minimal dose of the most exposed 2 cm3 of crit-
ical organ x (Gy), where x were rectum, bladder, or hips. 
In patients with not accomplishable BT, TT boost is 
performed with additional 18 Gy in 2 Gy fractions for the 
prostate gland, using a uniform CTV → PTV expansion 
margin of 0.5 cm if gold markers are implanted into the 
prostate and 0.8 cm if are not implanted [25,26]. For com-
parison, additional TT boost plans were created for every 
patient in the study with the same IMAT technique, and 
the total EQD2 doses of the most exposed volume of or-
gans at risks were calculated in these 3-step TT plans. 
Wilcoxon-matched pairs test was used (Statistica 12.5, 
StatSoft, Tulsa, OK, USA) to compare biological total dose 
of the combination of TT and BT or TT boost in the treat-
ment of prostate tumor. The comparison of our biological 
dose summation (BDS) and conventional UDC method 
was also performed with this statistical test. 
Results 
The mean prostate volume was 29.8 cm3 (range, 21.1-
43.0 cm3). We found that EQD2 D90 of the prostate was 
99.3 Gy (range, 96.8-101.9 Gy) using two-step TT and BT 
boost. The D0.1 and D2 of rectum were 62.8 Gy (range, 
41.0-75.6 Gy) and 50.3 Gy (range, 29.8-65.8 Gy). The D0.1 
of urethra was 96.1 Gy (range, 95.5-96.9 Gy), with the vol-
ume less than 2 cm3 in our cases. The D0.1 and D2 of blad-
der were 75.4 Gy (range, 62.5-92.9 Gy) and 64.7 Gy (range, 
46.0-73.8 Gy). The D0.1 and D2 of hips were 49.6 Gy (range, 
39.8-67.3 Gy) and 41.9 Gy (range, 33.5-58.3 Gy). 
In TT boost, the volume of PTV was larger than the pros-
tate and was 111.7 cm3 on average (range, 71.9-179.5 cm3). 
Comparing BT and TT boost, the D90 of prostate was sig-
nificantly higher with BT than with TT: 99.3 Gy vs. 77.9 Gy, 
p = 0.0034. The dose to rectum, bladder, and hips were 
significantly lower with BT boost, D2 was 50.3 Gy vs. 
76.8 Gy (p = 0.0117), 64.7 Gy vs. 78.3 Gy (p = 0.0117), and 
41.9 Gy vs. 50.6 Gy (p = 0.0044), respectively. Neverthe-
less, the dose to urethra was significantly higher with BT 
boost, D0.1 was 96.1 Gy vs. 79.3 Gy (p = 0.0180) using BT 
vs. TT boost technique (Figure 3). The detailed results are 
presented in Table 1. 
Comparing our dose summation method to the 
conventional UDC in combined TT and BT boost, we 
found that the UDC overestimated D2 of rectum by 37% 
Fig. 1. The BT treatment plan on the registered TT CT and BT US sets. A) A coronal view; B) 3D reconstruction; C) An axial 
view; D) A sagittal view. Thick red – prostate, thick green – rectum, thick yellow – urethra, thick orange – bladder, green, red, 
and yellow line – the 80%, 100%, and 120% isodose line
A
C
B
D
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(p = 0.0117), D2 of bladder by 5% (p = 0.0214), and under-
estimated D0.1 of urethra by 1% (p = 0.0277) (Table 2). 
Discussion 
Dose escalation has a fundamental role in radiother-
apy of intermediate- and high-risk prostate cancer [1,2]. 
Presently, there are no better alternatives of BT boost; 
however, several high-tech teletherapy techniques are 
possible competitors, such as image-guided and intensity- 
modulated teletherapy, arc therapy, helical tomotherapy, 
and stereotactic radiotherapy with linear accelerators or 
CyberKnife [3,7,16]. 
Vanneste et al. [1] reported a strong correlation be-
tween overall survival and D90 of prostate target volume 
in localized prostate cancer, with the best results being 
A
B C
Fig. 2. The most exposed 2 cm3 part (pink) of rectum (brown) in axial (A), in coronal (B), and in sagittal (C) slice of the TT CT
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Fig. 3. The EQD2 total doses of intensity-modulated arc 
therapy plus interstitial HDR-BT boost (BT), and intensity- 
modulated arc therapy plus teletherapy boost (TT)
D90 – minimum dose delivered to 90% of the prostate (Gy), D2 (rectum), 
D2 (bladder), D2 (hips) – minimal dose of the most exposed 2 cm
3 of 
rectum, bladder, and hips (Gy), D0.1 (urethra) – minimal dose of the most 
exposed 0.1 cm3 of urethra (Gy)
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achievable above 75.6 Gy EQD2. Different treatment tech-
niques showed similar curative rates, but with different 
toxicity patterns. The EQD2 prescribed dose to the pros-
tate with our fractionation scheme is 92.9 Gy using BT 
and 78 Gy with TT boost. At the same time, the dose to 
OARs is reduced with BT [3,4]. In our study, the use of 
IMAT TT with HDR-BT boost could keep the dose of 
Table 1. The EQD2 total doses of intensity-modulated arc therapy plus interstitial HDR-BT boost (TT + BT 
boost) and intensity-modulated arc therapy plus teletherapy boost (TT + TT boost)
EQD2 TT + BT boost TT + TT boost P-value* 
D90 (Gy) 99.3 (96.8-101.9) 77.9 (76.4-78.5) 0.0034 
D2 (rectum) (Gy) 50.3 (29.8-65.8) 76.8 (65.8-79.3) 0.0017 
D0.1 (urethra) (Gy) 96.1 (95.5-96.9) 79.3 (78.6-80.4) 0.0180 
D2 (bladder) (Gy) 64.7 (46.0-73.8) 78.3 (77.2-79.8) 0.0117 
D2 (hips) (Gy) 41.9 (33.5-58.3) 50.6 (43.6-58.1) 0.0044 
D90 – minimum dose delivered to 90% of the prostate (Gy), D2 (rectum), D2 (bladder), D2 (hips) – minimal dose of the most exposed 2 cm
3 of rectum, bladder, and hips 
(Gy), D0.1 (urethra) – minimal dose of the most exposed 0.1 cm
3 of urethra (Gy), *Wilcoxon-matched pairs test 
Table 2. The EQD2 total doses of intensity-modulated arc therapy plus interstitial HDR-BT boost calculated  
by our biological dose summation (BDS) and the uniform dose conception (UDC) method 
EQD2 BDS UDC P-value* 
D90 (Gy) 99.3 (96.8-101.9) 100.2 (96.6-104.8) 1.0000 
D2 (rectum) (Gy) 50.3 (29.8-65.8) 68.9 (66.6-70.9) 0.0117 
D0.1 (urethra) (Gy) 96.1 (95.5-96.9) 95.4 (94.4-96.0) 0.0277 
D2 (bladder) (Gy) 64.7 (46.0-73.8) 68.2 (62.9-74.0) 0.0214 
D90 – minimum dose delivered to 90% of the prostate (Gy), D2 (rectum), D2 (bladder) – minimal dose of the most exposed 2 cm
3 of rectum and bladder (Gy), 
D0.1 (urethra) – minimal dose of the most exposed 0.1 cm
3 of urethra (Gy), *Wilcoxon-matched pairs test 
all OARs under the tolerance level. The EQD2 D90 of the 
prostate was 99.3 Gy, while D2 of the rectum was 50.3 Gy, 
approximately half of the prostate dose. D0.1 dose to the 
urethra was 96.1 Gy on average, less than the prostate 
dose, despite the urethra being inside the prostate. D2 
dose to the bladder was 64.7 Gy, while for the hips, it was 
only 41.9 Gy. All dose to the hips originated from 60 Gy 
of TT, BT did not contribute to the dose. 
Even though in TT larger target volume is used than in 
BT, the total dose to the prostate was 22% less (21.4 Gy), D90 
was 99.3 Gy using BT and 77.9 Gy with TT boost. D2 dose 
to the rectum, bladder, and hips were 35% (26.5 Gy), 17% 
(13.6 Gy), and 18% (8.7 Gy) lesser with BT than using TT 
boost. 18 Gy IMAT TT boost to the prostate target volume 
instead of BT means extra 9 Gy dose to the hips. Only the 
dose to the urethra was higher with BT boost, D0.1 was 
18% (16.8 Gy) higher than using TT boost. Pieters et al. 
[17] concluded the same tendency in case of bladder, rec-
tum, and urethra for low-risk patients, where the target 
volume was only the prostate, and the total EQD2 was 76 
Gy using TT boost and 70 Gy using BT boost. The higher 
dose to the urethra using BT boost can account for more 
serious urethral toxicity in case of BT than TT boost. 
In previous publications, authors used the recom-
mended UDC method to estimate the total dose of pros-
tate and OARs in a combined therapy [15]. However, 
they did not consider the real biological doses. Kikuchi 
et al. [18] examined a better estimation of rectal dose 
than the UDC method, but they used a CT after remov-
ing the needles and US probe instead of a post-implant 
CT or actual US imaging in the intraoperative BT plan, 
and they did not take into account the quadratic behav-
ior of biological dose. Since the most exposed part of 
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Fig. 4. The most exposed 2 cm3 of rectum is indicated with brown, the urethra and the bladder are contoured with yellow and 
orange, and the prostate gland is shown with red (color wash) in axial (A) and sagittal (B) CT slice in two-step intensity-mod-
ulated arc therapy plan. Isodose lines: red – 60 Gy, yellow – 57 Gy, blue – 44 Gy, and green – 41.8 Gy
A B
the rectum, urethra, and bladder is the region, where 
the dose maximum is in BT, this most exposed 2 cm3 
can be used for the calculation of the total biological 
dose. In this small volume, the quadratic dependence 
is negligible. Thus, our dose summation method is sim-
ple, timesaving, and more personalized than the EUD 
method. The only more precise method would be the 
pixel-by-pixel calculation of biological dose in the same 
organ after a deformable registration of BT and TT im-
ages, but no treatment planning systems provides this 
possibility at present. 
The effect of dose summation technique on dose-vol-
ume parameters in combined TT and BT was also inves-
tigated in our study. The EQD2 D90 of the prostate was 
practically identical in our BDS and the conventional 
UDC method, but UDC overestimated the dose to rec-
tum by 37% (18.6 Gy), dose to bladder by 5% (3.5 Gy), 
and underestimated the dose to urethra by 1% (0.7 Gy) 
as compared to the BDS method. The cause may be 
that the dose of critical organs can be decreased with 
the IMAT technique, so the most exposed volumes of 
these organs can be irradiated with lower than the pre-
scribed dose. Accordingly, the potential advantage of 
BDS method is that it considers the most exposed part 
of OARs and thus sparing these parts from higher doses 
in TT, as shown in Figure 4. Overall, the dose to OARs 
can be reduced using our alternative dose summation 
method, therefore the treatment-related toxicity can be 
decreased. 
This study is the starting point of the development of 
an algorithm for the summation of TT and BT biologically 
effective doses, which uses an artificial intelligence-based 
DIR algorithm to match the critical anatomical structures 
in the two radiotherapy modalities. Further investiga-
tions are needed to assess whether our method predicts 
toxicity better than the recent UDC method. 
Conclusions 
Based on our biological dose summation method in 
IMAT TT with interstitial HDR-BT or IMAT TT boost 
treatment in prostate cancer, the total dose of the prostate 
is higher using BT boost than the TT. BT boost results in 
lower rectum, bladder, and hip doses, but higher dose to 
the urethra. UDC overestimates the rectum and bladder 
dose, and underestimates the dose to urethra, as com-
pared to our method. 
Disclosure 
This paper was supported by the János Bolyai Re-
search Scholarship of the Hungarian Academy of Scienc-
es and the ÚNKP-18-4 New National Excellence Program 
of the Ministry of Human Capacities. 
The authors report no conflict of interest.
References
1. Vanneste BG, Van Limbergen EJ, van Lin EN et al. Prostate 
cancer radiation therapy: what do clinicians have to know? 
Biomed Res Int 2016; 2016: 6829875.
2. Kuban DA, Tucker SL, Dong YL et al. Long-term results of 
the M. D. Anderson randomized dose-escalation trial for 
prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 67-74.
3. Georg D, Hopfgartner J, Gòra J et al. Dosimetric consider-
ations to determine the optimal technique for localized pros-
tate cancer among external photon, proton, or carbon-ion 
therapy and high-dose-rate or low-dose-rate brachytherapy. 
Int J Radiat Oncol Biol Phys 2014; 188: 715-722. 
4. Yang R, Zhao N, Liao A et al. Dosimetric and radiobiological 
comparison of volumetric modulated arc therapy, high-dose 
rate brachytherapy, and low-dose rate permanent seeds im-
plant for localized prostate cancer. Med Dosim 2016; 41: 236-241.
5. Kee DLC, Gal J, Falk AT et al. Brachytherapy versus exter-
nal beam radiotherapy boost for prostate cancer: Systematic 
review with meta-analysis of randomized trials. Cancer Treat 
Rev 2018; 70: 265-271.
Journal of Contemporary Brachytherapy (2020/volume 12/number 3)
Georgina Fröhlich, Péter Ágoston, Kliton Jorgo, et al.266
6. Fu-Min F, Yu-Ming W, Chong-Jong W et al. Comparison of 
the outcome and morbidity for localized or locally advanced 
prostate cancer treated by high-dose-rate brachytherapy plus 
external beam radiotherapy (EBRT) versus EBRT alone. Jpn 
J Clin Oncol 2008; 38: 474-479.
7. Morgan TM, Press RH, Cutrell PK et al. Brachytherapy for 
localized prostate cancer in the modern era: a comparison 
of patient-reported quality of life outcomes among different 
techniques. J Contemp Brachytherapy 2018; 10: 495-502.
8. Ash D, Al-Qaisieh B, Bottomley D et al. The correlation be-
tween D90 and outcome for I-125 seed implant monotherapy 
for localised prostate cancer. Radiother Oncol 2006; 79: 185-189.
9. Murakami N, Itami J, Okuma K et al. Urethral dose and in-
crement of international prostate symptom score (IPSS) in 
transperineal permanent interstitial implant (TPI) of prostate 
cancer. Strahlenther Onkol 2008; 184: 515-519.
10. Fowler JF. The linear-quadratic formula on progress in frac-
tionated radiotherapy. Br J Radiol 1989; 62: 679-694.
11. Nag S, Gupta N. A simple method of obtaining equivalent 
doses for use in HDR brachytherapy. Int J Radial Oncol Biol 
Phys 2000; 46: 507-513.
12. Niemierko A. Reporting and analyzing dose distributions: 
a concept of equivalent uniform dose. Med Phys 1997; 24: 103-
110.
13. Fröhlich G, Lang S, Berger D et al. Spatial relationship of the 
3D dose distribution from brachytherapy and external beam 
therapy for adding both dose plans in patients with cervix 
cancer. Brachytherapy 2008; 7: 95.
14. Fröhlich G, Vízkeleti J, Nguyen AN et al. Comparative anal-
ysis of image-guided adaptive interstitial brachytherapy and 
intensity-modulated arc therapy versus conventional treat-
ment techniques in cervix cancer using biological dose sum-
mation. J Contemp Brachytherapy 2019; 11: 69-75.
15. Pinkawa M, Fischedick K, Treusacherr P et al. Dose-vol-
ume impact in high-dose-rate Iridium-192 brachytherapy as 
a boost to external beam radiotherapy for localized prostate 
cancer- a phase II study. Radiother Oncol 2006; 78: 41-46.
16. Andrzejewski P, Kuess P, Knäusl B et al. Feasibility of dom-
inant intraprostatic lesion boosting using advanced photon-, 
proton- or brachytherapy. Radiother Oncol 2015; 117: 509-514.
17. Pieters BR, van de Kamer JB, van Herten YR et al. Compar-
ison of biologically equivalent dose-volume parameters for 
the treatment of prostate cancer with concomitant boost 
IMRT versus IMRT combined with brachytherapy. Radiother 
Oncol 2008; 88: 46-52.
18. Kikuchi K, Nakamura R, Tanji S et al. Three-dimensional 
summation of rectal doses in brachytherapy combined with 
external beam radiotherapy for prostate cancer. Radiother On-
col 2013; 107: 159-164. 
19. Kovács G, Pötter R, Loch T et al. GEC/ESTRO-EAU recom-
mendations on temporary brachytherapy using stepping 
sources for localised prostate cancer. Radiother Oncol 2005; 
74: 137-148.
20. Fröhlich G, Ágoston P, Lövey J et al. Dosimetric evaluation 
of high-dose-rate interstitial brachytherapy boost treatments 
for localized prostate cancer. Strahlenther Onkol 2010; 186: 
388-395.
21. Ágoston P, Major T, Fröhlich G et al. Moderate dose escala-
tion with single-fraction high-dose-rate brachytherapy boost 
for clinically localized intermediate- and high-risk prostate 
cancer: 5-year outcome of the first 100 consecutively treated 
patients. Brachytherapy 2011; 10: 376-384.
22. Dasu A, Toma-Dasu I. Prostate alpha/beta revisited – an 
analysis of clinical results from 14 168 patients. Act Oncol 
2012; 51: 963-974.
23. Leborgne F, Fowler J, Jos Y et al. Later outcomes and alpha/
beta estimate from hypofractionated conformal three-di-
mensional radiotherapy versus standard fractionation for 
localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 
82: 1200-1207.
24. Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta 
ratio for prostate cancer in the presence of an overall time 
factor: bad news, good news, or no news? Int J Radiat Oncol 
Biol Phys 2013; 85: 89-94.
25. Boehmer D, Maingon P, Poortmans P et al. EORTC radiation 
oncology group. Guidelines for primary radiotherapy of pa-
tients with prostate cancer. Radiother Oncol 2006; 79: 259-269.
26. Lawton CA, Michalski J, El-Naqa I et al. RTOG GU Radiation 
oncology specialists reach consensus on pelvic lymph node 
volumes for high-risk prostate cancer. Int J Radiat Oncol Biol 
Phys 2009; 74: 383-387.
